Orchid Pharma Ltd
Orchid Pharma Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement. FY27 growth guidance is cautious; management is not providing specific growth numbers currently.
From Orchid Pharma Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement.
- Management expects better Q-o-Q growth in H2 FY27, as regulated market demand typically picks up in the winter season.
- Volumes for key products like Exblifep in Europe exhibited significant sequential growth (300% in Q3 FY26, 170% in Q4 FY26, and 50% in Q1 FY27).
- The 7-ACA Jammu facility aims for commercial batch by March 2027 with ramp-up to 80-100% utilization by year-end.
- Long-term revenue from new products like Enmetazobactam has $1-2 billion lifetime sales potential.
- NP-NC segment sales were INR 21 crores in the recent quarter with ongoing incremental product additions.
- Management maintains long-term revenue guidance of $1.1 billion to $2 billion from key assets and expects steady volume growth through product mix improvement and new launches.
- Pricing and demand remain competitive; growth will be gradual rather than straight-line.
Profitability & Margins
See what Orchid Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex is not expected to be very significant as major projects are nearing completion (Page 8).
- INR 750 crores capex for the 7-ACA project (Page 8).
- USD 20-25 million capex for the cefiderocol project (Page 8).
- Current financial year will see completion of cefiderocol and 7-ACA projects (Page 5).
- Strategic focus on backward integration into 7-ACA and cefiderocol access project to create diversified value (Page 5).
- Ongoing cost discipline and operational discipline to complement capital projects (Page 5).
- No specific large-scale capex planned beyond FY27 mentioned; potential extensions or additional investments may depend on successful plant startups (Page 17).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Orchid Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Orchid Pharma as of August 2026.
- However, management highlighted ongoing engagement in several advanced discussions for product launches and partnerships across global markets including Latin America, Southeast Asia, U.S., China, South America, Mexico, Philippines, Thailand, Morocco, and Australia.
- Projects like the cefiderocol manufacturing and the 7-ACA fermentation facility are on schedule, with commercial launch expected post-approval in early 2027.
- The Exblifep licensing agreement in Russia is valued at approximately USD178 million over 10 years, but revenue will depend on registration, launch, and market development over time.
- The company is working closely with GARDP for broader global market access for cefiderocol, upon finalization of distributor agreements.
- Therefore, while specific order book numbers are not disclosed, the company is actively building a pipeline through regulatory approvals, partnerships, and new product launches.
Orchid Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹24 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Orchid Pharma Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Orchid Pharma Ltd Q1 FY27 results?
Q1 FY27 showed 15% YoY revenue growth and a 3 percentage point gross margin improvement. FY27 growth guidance is cautious; management is not providing specific growth numbers currently.
What is Orchid Pharma Ltd share price analysis?
Orchid Pharma Ltd currently shows a below-average growth signal. The stock trades at a P/E of 332.3 with a market cap of ₹6,001 Cr. Investors should review the full earnings analysis for detailed insights.
Is Orchid Pharma Ltd planning capital expenditure?
FY27 capex is not expected to be very significant as major projects are nearing completion (Page 8).
Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.